Last reviewed · How we verify
Panblok
Panblok is a Biologic drug developed by Protein Sciences Corporation. It is currently in Phase 1 development. Also known as: recombinant hemagglutinin, rHA.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Panblok |
|---|---|
| Also known as | recombinant hemagglutinin, rHA |
| Sponsor | Protein Sciences Corporation |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older (PHASE1, PHASE2)
- Panblok H7 Vaccine Adjuvanted With AS03 or MF59 (PHASE2)
- Recombinant H7 Hemagglutinin Influenza Vaccine Trial (PHASE1)
- Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PHASE1, PHASE2)
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (PHASE1, PHASE2)
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panblok CI brief — competitive landscape report
- Panblok updates RSS · CI watch RSS
- Protein Sciences Corporation portfolio CI
Frequently asked questions about Panblok
What is Panblok?
Who makes Panblok?
Is Panblok also known as anything else?
What development phase is Panblok in?
Related
- Manufacturer: Protein Sciences Corporation — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: recombinant hemagglutinin, rHA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing